object
cineol
mucolyt
bronchodil
antiinflammatori
properti
reduc
exacerb
rate
patient
suffer
copd
well
amelior
symptom
patient
suffer
asthma
rhinosinus
base
effect
therefor
postul
hypothesi
patient
acut
bronchiti
would
also
benefit
therapi
cineol
method
part
doubleblind
placebocontrol
multicenterstudi
total
patient
confirm
acut
bronchiti
randomli
select
particip
period
day
patient
administ
x
mg
cineol
respect
placebo
per
day
primari
outcom
measur
bronchiti
sum
score
summaris
relev
symptom
acut
bronchiti
result
day
treatment
notabl
patient
group
treat
cineol
show
significantli
improv
bronchitissumscor
placebo
group
p
statist
signific
differ
individu
outcom
measur
especi
underlin
frequenc
cough
fit
p
day
effect
cineol
treatment
acut
bronchiti
clearli
measur
could
proven
treatment
period
mere
day
studi
corrobor
fact
cineol
activ
significantli
reduc
cough
frequenc
four
day
therefor
shown
great
socioeconom
impact
trial
registr
isrctn
acut
bronchiti
one
common
reason
patient
visit
ambulatori
care
physician
frequent
develop
cours
common
cold
predomin
symptom
dri
product
cough
averag
practic
visit
acut
bronchiti
result
prescript
antibiot
although
predominantli
caus
viral
infect
evidencebas
review
metaanalys
random
control
trial
conclud
routin
antibiot
treatment
provid
major
clinic
benefit
adult
acut
bronchiti
primari
goal
reduct
frequenc
cough
fit
wherea
treatment
antituss
recommend
reserv
specif
except
mucolyt
agent
aromat
essenti
oil
eucalyptu
peppermint
oil
long
histori
treatment
respiratori
inflamm
main
constitu
eucalyptu
oil
cineol
proven
effect
treatment
respiratori
diseas
rhinosinus
asthma
copd
essenti
due
mucolyt
primari
antiinflammatori
effect
therefor
clinic
effect
cineol
repeatedli
proven
establish
context
control
clinic
studi
cineol
acceler
beat
frequenc
cilia
mucou
membran
well
act
bronchodil
antiinflammatori
agent
postul
effect
treat
symptom
acut
bronchiti
therefor
order
investig
therapeut
effect
cineol
treatment
acut
bronchiti
conduct
random
placebocontrol
multicent
studi
randomis
doubleblind
placebocontrol
parallelgroup
studi
conduct
practic
gener
practition
specialist
pneumolog
intern
medicin
ent
practic
accord
helsinki
declar
studi
approv
appropri
author
ethic
committe
respons
particip
center
furthermor
patient
provid
explicit
written
consent
form
prior
particip
commenc
studi
patient
randomli
assign
one
two
treatment
group
stratif
accord
clinic
center
patient
given
necessari
dose
capsul
contain
either
mg
cineol
activ
ingredi
dosag
group
amount
capsul
taken
time
daili
result
total
dose
mg
cineol
per
day
placebo
control
group
receiv
equal
dose
placebo
capsul
order
avoid
patient
recognis
smell
cineol
patient
instruct
take
capsul
miner
water
half
hour
meal
capsul
contain
either
activ
substanc
placebo
organolept
ident
seal
blister
stripe
patient
visit
practic
begin
studi
well
subsequ
day
diagnosi
acut
bronchiti
confirm
accord
criteria
wenzel
studi
limit
adult
patient
age
year
diagnosi
acut
bronchiti
longer
day
elig
particip
bronchitissumscor
higher
patient
exclud
sever
medic
condit
relev
influenc
acut
bronchiti
primari
endpoint
bronchitissumscor
summaris
relev
symptom
acut
bronchiti
defin
multipl
criteria
compos
paramet
dyspnea
sputum
frequenc
cough
thorac
pain
auscult
lung
functional
equal
weight
specifi
intens
dyspnea
score
difficulti
breath
minor
difficulti
breath
moder
difficulti
breath
sever
difficulti
breath
unbear
difficulti
breath
quantiti
secret
assess
score
secret
ml
ie
modest
ml
ie
modest
ml
ie
moder
ml
ie
distinct
frequenc
cough
fit
document
accord
patient
diari
score
cough
fit
per
day
one
cough
fit
per
day
cough
fit
per
day
ie
occasion
cough
fit
per
day
cough
fit
per
day
ie
frequent
cough
fit
per
day
unbear
often
thorac
pain
cough
measur
score
modest
moder
sever
pain
unbear
pain
find
auscult
measur
score
modest
moder
rel
distinct
distinct
rale
impair
lung
function
differenti
score
slight
predict
valu
moder
predict
valu
strong
predict
valu
strong
impair
less
predict
valu
addit
symptomscor
determin
dyspnea
frequenc
intens
rest
well
exercis
score
caus
problem
occasion
problem
caus
lot
problem
import
problem
patient
frequenc
dyspnea
cours
week
also
gaug
convert
qualit
score
score
day
good
day
good
day
good
nearli
everi
day
good
everi
day
good
addit
cough
propens
cough
determin
given
score
cough
morn
without
complaint
morn
complaint
morn
day
moder
morn
day
sever
continu
whole
day
moder
complaint
continu
whole
day
relev
complaint
randomis
sequenti
assign
balanc
block
computergener
list
random
idv
dataanalysi
studi
plan
kraill
germani
randomis
follow
patient
detail
record
height
weight
age
time
first
diagnosi
asthma
symptom
document
allergi
concomit
diseas
prescrib
medic
assess
current
mainten
therapi
control
visit
carri
day
advers
event
record
complianc
treatment
plan
well
potenti
chang
therapi
address
propos
sampl
size
studi
total
patient
treatment
group
nnpar
nonparametr
idv
dataanalysi
studi
plan
kraill
germani
analysi
efficaci
perform
intentiontotreatpopul
includ
elig
patient
receiv
least
one
dose
medic
least
one
followup
visit
primari
outcom
measur
compos
bronchitissumscor
statist
analysi
data
analys
use
wilcoxonmannwhitneyu
test
idv
dataanalysi
studi
plan
krail
germani
secondari
outcom
measur
analys
use
wilcoxonmannwhitneyu
test
well
data
express
mean
valu
sd
test
twotail
pvalu
less
consid
indic
statist
signific
total
patientsrepres
reallif
popul
randomis
februari
januari
receiv
least
one
dose
studi
medic
treatment
group
well
match
respect
baselin
characterist
tabl
mean
age
particip
entri
year
respect
group
mean
durat
patient
acut
bronchiti
day
respect
medic
gener
chang
day
treatment
period
baselin
paramet
treatment
group
compar
treatment
complianc
determin
count
studi
medic
visit
found
high
compar
across
treatment
group
primari
outcom
measur
bronchitissumscor
compos
intens
dyspnea
quantiti
secret
frequenc
cough
fit
thorac
pain
cough
rale
accord
auscult
impair
lung
function
day
treatment
mean
decreas
scorepoint
cineol
group
scorepoint
placebogroup
tabl
differ
treatment
group
statist
signific
day
p
due
amelior
symptom
seven
ten
day
without
medic
differ
treatment
group
found
distinct
yet
statist
signific
controlvisit
day
point
differ
calcul
comparison
singl
paramet
bronchitissumscor
gener
fail
show
statist
signific
differ
treatment
group
except
frequenc
cough
fit
statist
signific
individu
paramet
could
also
proven
influenc
treatment
compar
basi
frequenc
cough
fit
day
p
measur
cough
document
score
gener
use
field
research
predomin
paramet
cough
show
characterist
differ
treatment
tabl
therefor
compar
cough
rather
cough
frequenc
requir
correct
definit
order
show
differ
progress
symptom
safeti
examin
carri
patient
administ
studi
medic
within
placebo
group
assum
two
recognis
record
advers
event
eg
gastrointestin
infect
relat
studi
medic
wherea
ae
interpret
relat
intoler
studi
medic
ie
heartburn
burn
mouth
treatment
cineol
advers
event
report
relat
studi
medic
otiti
sinus
eye
burn
headach
one
case
patient
complain
stomachach
interpret
relat
studi
medic
note
differ
two
treatment
group
neither
clinic
relev
statist
signific
safeti
examin
studi
particip
patient
highlight
notabl
differ
two
treatment
group
number
control
clinic
trial
acut
bronchiti
carri
view
investig
antibiot
result
shown
antibiot
prescrib
care
medic
fail
mucolyt
remedi
tradit
use
europ
control
clinic
trial
base
cineol
main
constitu
eucalyptu
oil
yet
carri
patient
acut
bronchiti
trial
clinic
relev
paramet
reduct
cough
frequenc
statist
signific
effect
favour
cineol
could
proven
due
proven
antiinflammatori
mucolyt
effect
activ
ingredi
acut
bronchiti
character
cough
persist
day
patient
produc
purul
sputum
repres
slough
tracheobronchi
epithelium
inflammatori
cell
rapid
diagnost
test
identifi
specif
pathogen
normal
recommend
case
acut
bronchiti
caus
viral
infect
major
pathogen
influenza
b
virus
parainfluenza
viru
respiratori
syncyti
viru
corona
viru
adenoviru
rhinoviru
know
pathophysiolog
seem
evid
antibiot
first
choic
treatment
therefor
treatment
focu
treatment
option
known
favour
influenc
pathophysiolog
abl
reduc
symptom
acut
bronchiti
without
limit
rel
high
incid
side
effect
mucociliari
dysfunct
direct
clinic
implic
pathophysiolog
mechan
acut
bronchiti
base
known
antiinflammatori
bronchodil
effect
natur
substanc
cineol
assum
activ
ingredi
therapeut
benefici
patient
acut
bronchiti
thu
repres
necessari
paramet
use
effect
therapi
import
point
establish
correct
point
time
paramet
progress
symptom
measur
view
context
durat
exist
diagnosi
acut
bronchiti
major
concern
practis
minor
patient
visit
physician
immedi
follow
recognit
first
symptom
acut
bronchiti
therefor
recruit
patient
basi
symptom
last
longer
day
mean
durat
sinc
occurr
acut
bronchiti
symptom
four
day
thu
surpris
differ
two
group
follow
day
treatment
studi
medic
longer
show
statist
signific
treatment
period
day
efficaci
cineol
compar
placebo
could
proven
differ
group
base
upon
symptomsumscor
frequenc
cough
fit
decreas
day
due
normal
cours
symptom
without
treatment
diseas
consid
mean
durat
begin
treatment
symptom
acut
bronchiti
also
subsid
without
treatment
effect
medic
therefor
show
statist
signific
differ
day
treatment
seen
contribut
rapid
onset
efficaci
cineol
treat
acut
bronchiti
interpret
result
studi
corrobor
import
select
effect
sumscor
studi
investig
could
clearli
show
number
cough
fit
relev
paramet
chosen
demonstr
progress
diseas
paramet
acut
bronchiti
sumscor
base
relev
symptom
acut
bronchiti
without
show
equival
improv
comparison
frequenc
cough
fit
explan
find
baselin
paramet
requir
clear
definit
inand
exclus
criteria
plan
studi
demonstr
efficaci
paramet
cough
main
predomin
criterion
definit
acut
bronchiti
paramet
minor
influenc
result
definit
cough
document
specifi
score
cough
morn
without
complaint
morn
complaint
morn
day
moder
morn
day
sever
continu
whole
day
moder
complaint
continu
whole
day
relev
complaint
paragraph
outcom
measur
cineol
effect
treat
acut
bronchiti
explain
proven
pharmacodynam
pharmacolog
properti
clinic
studi
antiinflammatori
also
mucolyt
effect
could
proven
patient
rhinosinus
copd
asthma
find
complementari
former
result
sinc
shown
antituss
effect
also
base
amelior
inflamm
mucociliari
clearanc
patient
acut
bronchiti
result
view
context
fact
disord
affect
approxim
adult
annual
belong
common
ill
among
outpati
socioeconom
relev
compound
short
time
frame
relief
cough
cough
fit
achiev
without
necess
treatment
antibiot
amelior
main
symptom
frequenc
cough
occur
without
signific
increas
cost
comparison
treatment
option
